Standard BioTools shares surge 19.14% after-hours as preliminary 2025 revenue exceeds guidance, cost cuts boost profitability outlook.
ByAinvest
Thursday, Jan 8, 2026 4:15 pm ET1min read
LAB--
Standard BioTools Inc. (NASDAQ: LAB) surged 19.14% in after-hours trading following the announcement of preliminary 2025 revenue results exceeding expectations. The company reported Q4 2025 combined revenue of $56 million and full-year revenue of $185 million, both above guidance. Management highlighted cost optimization efforts that improved operating efficiency and positioned the base business toward positive adjusted EBITDA. Additionally, the pending sale of SomaLogic to Illumina, expected to close in H1 2026, is projected to generate $550 million in cash, enhancing strategic flexibility for M&A. These developments underscore strong execution amid macroeconomic challenges and reinforce investor confidence in the company’s path to profitability and growth.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet